Portal de Periódicos da CAPES

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS ‐mutant melanoma

2014; Wiley; Volume: 27; Issue: 6 Linguagem: Inglês

10.1111/pcmr.12303

1755-148X

Vito W. Rebecca, Gretchen M. Alicea, Kim H.T. Paraiso, Harshani R. Lawrence, Geoffrey T. Gibney, Keiran S.M. Smalley,

Cancer Mechanisms and Therapy

The MEK inhibitor MEK162 is the first targeted therapy agent with clinical activity in patients whose melanomas harbor NRAS mutations; however, median PFS is 3.7 months, suggesting the rapid onset of resistance in the majority of patients. Here, we show that treatment of NRAS-mutant melanoma cell lines with the MEK inhibitors AZD6244 or trametinib resulted in a rebound activation of phospho-ERK (pERK). Functionally, the recovery of signaling was associated with the maintenance of cyclin-D1 expression and therapeutic escape. The combination of a MEK inhibitor with an ERK inhibitor suppressed the recovery of cyclin-D1 expression and was associated with a significant enhancement of apoptosis and the abrogation of clonal outgrowth. The MEK/ERK combination strategy induced greater levels of apoptosis compared with dual MEK/CDK4 or MEK/PI3K inhibition across a panel of cell lines. These data provide the rationale for further investigation of vertically co-targeting the MAPK pathway as a potential treatment option for NRAS-mutant melanoma patients.